Hypersensitivity reactions to vaccines in children: from measles to SARS‐CoV‐2

Allergic individuals at risk for hypersensitivity reactions to measles vaccine marketed for a long time are well established. On the other hand, risk factors for hypersensitivity reactions to the new mRNA COVID‐19 vaccines currently include a history of allergy, allergy to excipient of the vaccine,...

Descripción completa

Detalles Bibliográficos
Autores principales: Caffarelli, Carlo, Liotti, Lucia, Bianchi, Annamaria, Bottau, Paolo, Caimmi, Silvia, Crisafulli, Giuseppe, Franceschini, Fabrizio, Paglialunga, Claudia, Saretta, Francesca, Mori, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Special Issue: 2021 Update From The Italian Society Of Pediatric Allergy And Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303687/
https://www.ncbi.nlm.nih.gov/pubmed/35080320
http://dx.doi.org/10.1111/pai.13631
_version_ 1784751928741199872
author Caffarelli, Carlo
Liotti, Lucia
Bianchi, Annamaria
Bottau, Paolo
Caimmi, Silvia
Crisafulli, Giuseppe
Franceschini, Fabrizio
Paglialunga, Claudia
Saretta, Francesca
Mori, Francesca
author_facet Caffarelli, Carlo
Liotti, Lucia
Bianchi, Annamaria
Bottau, Paolo
Caimmi, Silvia
Crisafulli, Giuseppe
Franceschini, Fabrizio
Paglialunga, Claudia
Saretta, Francesca
Mori, Francesca
author_sort Caffarelli, Carlo
collection PubMed
description Allergic individuals at risk for hypersensitivity reactions to measles vaccine marketed for a long time are well established. On the other hand, risk factors for hypersensitivity reactions to the new mRNA COVID‐19 vaccines currently include a history of allergy, allergy to excipient of the vaccine, or hypersensitivity reactions to the first dose of COVID‐19 vaccine. In the last two cases, the recipient should be assessed by an allergist before vaccination to share a decision on the choice of vaccination. Studies on skin testing accuracy and desensitization protocols to the COVID‐19 vaccines and the efficacy of potential alternatives in patients with confirmed hypersensitivity reactions to the first COVID‐19 vaccine are necessary to improve the safety of COVID‐19 vaccines.
format Online
Article
Text
id pubmed-9303687
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93036872022-07-28 Hypersensitivity reactions to vaccines in children: from measles to SARS‐CoV‐2 Caffarelli, Carlo Liotti, Lucia Bianchi, Annamaria Bottau, Paolo Caimmi, Silvia Crisafulli, Giuseppe Franceschini, Fabrizio Paglialunga, Claudia Saretta, Francesca Mori, Francesca Pediatr Allergy Immunol Special Issue: 2021 Update From The Italian Society Of Pediatric Allergy And Immunology Allergic individuals at risk for hypersensitivity reactions to measles vaccine marketed for a long time are well established. On the other hand, risk factors for hypersensitivity reactions to the new mRNA COVID‐19 vaccines currently include a history of allergy, allergy to excipient of the vaccine, or hypersensitivity reactions to the first dose of COVID‐19 vaccine. In the last two cases, the recipient should be assessed by an allergist before vaccination to share a decision on the choice of vaccination. Studies on skin testing accuracy and desensitization protocols to the COVID‐19 vaccines and the efficacy of potential alternatives in patients with confirmed hypersensitivity reactions to the first COVID‐19 vaccine are necessary to improve the safety of COVID‐19 vaccines. John Wiley and Sons Inc. 2022-01-25 2022-01 /pmc/articles/PMC9303687/ /pubmed/35080320 http://dx.doi.org/10.1111/pai.13631 Text en © 2022 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Special Issue: 2021 Update From The Italian Society Of Pediatric Allergy And Immunology
Caffarelli, Carlo
Liotti, Lucia
Bianchi, Annamaria
Bottau, Paolo
Caimmi, Silvia
Crisafulli, Giuseppe
Franceschini, Fabrizio
Paglialunga, Claudia
Saretta, Francesca
Mori, Francesca
Hypersensitivity reactions to vaccines in children: from measles to SARS‐CoV‐2
title Hypersensitivity reactions to vaccines in children: from measles to SARS‐CoV‐2
title_full Hypersensitivity reactions to vaccines in children: from measles to SARS‐CoV‐2
title_fullStr Hypersensitivity reactions to vaccines in children: from measles to SARS‐CoV‐2
title_full_unstemmed Hypersensitivity reactions to vaccines in children: from measles to SARS‐CoV‐2
title_short Hypersensitivity reactions to vaccines in children: from measles to SARS‐CoV‐2
title_sort hypersensitivity reactions to vaccines in children: from measles to sars‐cov‐2
topic Special Issue: 2021 Update From The Italian Society Of Pediatric Allergy And Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303687/
https://www.ncbi.nlm.nih.gov/pubmed/35080320
http://dx.doi.org/10.1111/pai.13631
work_keys_str_mv AT caffarellicarlo hypersensitivityreactionstovaccinesinchildrenfrommeaslestosarscov2
AT liottilucia hypersensitivityreactionstovaccinesinchildrenfrommeaslestosarscov2
AT bianchiannamaria hypersensitivityreactionstovaccinesinchildrenfrommeaslestosarscov2
AT bottaupaolo hypersensitivityreactionstovaccinesinchildrenfrommeaslestosarscov2
AT caimmisilvia hypersensitivityreactionstovaccinesinchildrenfrommeaslestosarscov2
AT crisafulligiuseppe hypersensitivityreactionstovaccinesinchildrenfrommeaslestosarscov2
AT franceschinifabrizio hypersensitivityreactionstovaccinesinchildrenfrommeaslestosarscov2
AT paglialungaclaudia hypersensitivityreactionstovaccinesinchildrenfrommeaslestosarscov2
AT sarettafrancesca hypersensitivityreactionstovaccinesinchildrenfrommeaslestosarscov2
AT morifrancesca hypersensitivityreactionstovaccinesinchildrenfrommeaslestosarscov2

Ejemplares similares